PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Diclofenac sodium with misoprostol - Pain & inflammation - musculoskeletal

PAD Profile : Diclofenac sodium with misoprostol - Pain & inflammation - musculoskeletal

Keywords :
NSAIDs, rheumatism, PNMP, musculoskeletal pain, rheumatic disease, rheumatoid arthritis, osteoarthritis
Brand Names Include :
Arthrotec

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Safety Information
01 July 2022

Committee Recommendations

Date
Committee Name
Narrative
07 August 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

A stepped approach to pain management is recommended. Paracetamol is considered a 1st line option for the treatment of pain. Consider initiation of  oral NSAID (ibuprofen or naproxen) as an adjunct to paracetamol if required.  Diclofenac or celecoxib (first line COX 2) may be considered as alternatives when ibuprofen and naproxen are ineffective / not tolerated. See the guidelines attached for further information

PLEASE NOTE: Diclofenac with misoprostil is considered BLACK on the traffic light system and is not recommended for use in any healthcare setting across the Surrey & North West Sussex health economy.

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.01. Non-steroidal anti-inflammatory drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More